New Rewards Coming Soon!¡Se vienen nuevas recompensas!
Our Healthy Rewards Program is getting an update in September! For a sneak peek of all the changes - including new rewards and ways to redeem them - please click here.
¡Nuestro Programa Healthy Rewards tendrá su actualización en septiembre! Para ver un adelanto de todos los cambios, incluyendo nuevas recompensas y formas de canjearlas, haz clic aquí.
Call to action: The purpose of this communication is to inform providers that on January 1, 2025, Texas Medicaid & Healthcare Partnership (TMHP) updated the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook, section 6.104, “Ravulizumab-cwvz (Ultomiris)” and section 6.14, “Azacitidine (Vidaza).”
The following updates were made:
Diagnosis code G360 will be added as a payable diagnosis for ravulizumab-cwvz (Ultomiris) (procedure code J1303).
Diagnosis code C9200 will be added as a payable diagnosis for azacitidine (Vidaza) (procedure code J9025).
Next steps: Providers should share this communication with their staff.